Search
Fludarabine
go.drugbank.com/drugs/DB01073ApprovedInvestigationalFludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Categories: DNA (Cytosine-5-)-Methyltransferases, antagonists & inhibitorsProducts: DARABIN 50 MG IV ENJEKSIYON/INFÜZYON ICIN LIYOFILIZE TOZ IÇEREN FLAKON ,5 FLAKON, FLUDALYM 50 MG/2 ML IV ENJEKSİYON/İNFÜZYON İÇİN LİYOFİLİZE TOZ İÇEREN FLAKON, 1 ADETGuselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalDeveloped by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. … IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].
Products: TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADETSoybean oil
go.drugbank.com/drugs/DB09422ApprovedInvestigationalIt is a complex mixture of triglycerides where per 100 g, soybean oil has 16 g of saturated fat, 23 g of monounsaturated fat, and 58 g of polyunsaturated fat. … The major component fatty acids are linoleic (48% - 58%), oleic (17% - 30%), palmitic (9% -13%), linolenic (4% - 11%), and stearic (2.5% - 5.0%).
Mixtures: LIPOFUNDIN MCT/LCT %10 VIT E INFUZYON ICIN YAG EMULSUYONU, 100 ML, LIPOFUNDIN %10 MCT/LCT VIT ELI 500 ML IV SOL.Products: INTRALIPID %10 500 ML YAG EMULSIYONU, INTRALIPID %20 100 ML YAG EMULSIYONUMethoxsalen
go.drugbank.com/drugs/DB00553ApprovedInvestigationalA naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2A6 InhibitorsSynonyms: 8-MP, O-methylxanthotoxolPiracetam
go.drugbank.com/drugs/DB09210ApprovedWithdrawnOriginally marketed by UCB Pharma in 1971, piracetam was the first nootropic drug to modulate cognitive function without causing sedation or stimulation [A31532]. … Evidence to support its use for many conditions is unclear.
Products: NOTROSERB 1 G IM/IV ENJEKSİYONLUK ÇÖZELTİ , 100 ADET, CEREBROFIL 800 MG FİLM TABLET, 50 ADETBuprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approved[A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such … Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist
Mixtures: Suboxone 8 mg/2 mg sublingual tablets, Suboxone 2 mg/0.5 mg sublingual tabletsCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesBusulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalIt has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: BUSULFAN SOLUCIÓN INYECTABLE 60 MG/10 ML, MYLERAN 2 MG TABLET, 100 ADETIsatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigationalFollowing three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was … [L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa.[L12102]
Products: SARCLİSA 100 MG/5 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADET, SARCLİSA 500 MG/25 ML IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN KONSANTRE, 1 ADETMoclobemide
go.drugbank.com/drugs/DB01171ApprovedInvestigationalA reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder. … Due to negligible anticholinergic and antihistaminic actions, moclobemide has been better tolerated than tri- or heterocyclic antidepressants [A31901].
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 SubstratesProducts: ZOPRAX TABLETAS 100 MG, MOCLOBEMID-NEURAX 150 MGRamucirumab
go.drugbank.com/drugs/DB05578ApprovedInvestigationalBy binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, … In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it.
Products: CYRAMZA 500 MG/50 ML İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇEREN FLAKON, 1 ADET, CYRAMZA 100MG/10 ML INFÜZYONLUK ÇÖZELTI KONSANTRESI IÇEREN FLAKON, 1 ADET